Bio-Thera's BAT2506 Receives NMPA Approval as China's First Golimumab Biosimilar

Bio-Thera Solutions Receives NMPA Approval for BAT2506

Bio-Thera Solutions, a prominent biopharmaceutical company based in Guangzhou, China, has recently announced a significant milestone: the approval of its golimumab biosimilar, BAT2506, by the National Medical Products Administration (NMPA). This marks the first-ever approval for a golimumab biosimilar in China. The product will be marketed under the name 阿舒立 (ASHULI) and is approved for the treatment of rheumatoid arthritis and ankylosing spondylitis, both chronic autoimmune conditions that affect a considerable number of patients in the region.

Golimumab is recognized as a human IgG1 monoclonal antibody that specifically targets tumor necrosis factor alpha (TNF-α), a key player in the inflammatory process. By binding to TNF-α, golimumab effectively reduces a variety of inflammatory markers including C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF). This mechanism makes it a crucial option for patients suffering from autoimmune diseases who require effective treatment to manage their symptoms and overall health.

The necessity for affordable biological agents is especially pronounced in China, where countless individuals live with autoimmune diseases. The introduction of 阿舒立 (ASHULI) is poised to provide a new, cost-effective option for these patients, enhancing their accessibility to essential therapies. Shengfeng Li, CEO of Bio-Thera Solutions, expressed pride in reaching this pivotal achievement, noting that this is the sixth biosimilar developed by the company to receive NMPA approval. He emphasized the crucial role biosimilars play in broadening patient access to highly beneficial biologics.

Furthermore, Bio-Thera has already established commercialization agreements covering several regions worldwide. These agreements target countries including the United States, Europe, Canada, and extend to the Middle East, North Africa, Latin America, and Southeast Asia. Such initiatives underscore the company’s commitment to catering to the global needs of autoimmune patients, significantly expanding the reach of BAT2506.

Bio-Thera Solutions, Ltd. dedicates itself to innovating therapies for a diverse set of medical conditions, including cancer, autoimmune disorders, cardiovascular issues, and eye diseases. In their ongoing efforts to address unmet medical needs, they have successfully advanced multiple biopharmaceutical candidates into late-stage development, demonstrating their capability in the highly competitive biopharmaceutical landscape.

Additionally, the company is not only focusing on biosimilars. With over 20 promising candidates currently undergoing various stages of clinical trials, Bio-Thera is exploring advancements in immuno-oncology in the post-PD-1 era and developing targeted therapies using antibody-drug conjugates (ADCs).

Regarding the importance of their new golimumab biosimilar, Bio-Thera’s progress illustrates a commitment to providing innovative solutions for managing autoimmune diseases in China and beyond. As the company pursues further development, stakeholders and healthcare providers remain hopeful that this approval will significantly enhance therapeutic options available to patients in need.

For further information on Bio-Thera and their products, visit Bio-Thera Solutions.

As the landscape of biotechnology continues to evolve, this approval not only reflects Bio-Thera’s ingenuity in developing biosimilars but also highlights the growing demand for accessible, effective treatment solutions in the realm of autoimmune diseases.